

## Small Cap Sundowner Series

**James Bonnar**Managing Director and CEO

26 November 2025 | Sydney, Australia

**Improving Lives, Offering Hope** 

**ASX:NYR** 

Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.



## Important Notice and Disclaimer



This presentation has been prepared by Nyrada Inc ("NYR" or "Company"). It should not be considered as an offer or invitation to subscribe for, or purchase any securities in NYR, or as an inducement to purchase any securities in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. In particular, this presentation may not be released to US wire services or distributed in the United States.

This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or to, or for the account or benefit of, US persons. The Company's CDIs have not been, and will not be, registered under the US Securities Act or the securities laws of any state or other jurisdiction of the United States. The CDIs may not be offered, sold or otherwise transferred in the United States except in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act of 1933 and the applicable securities laws of any state or other jurisdiction in the United States. No person in the United States may, directly or indirectly, participate in the Company's Security Purchase Plan.

It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice, and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place.

Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

## **Nyrada Inc**

(ASX: NYR)

Problem

Approach

Results / Traction

\$163M\* Market Cap · Phase IIa Ready · Cardiology Disruption · Platform Technology


## Xolatryp™ — First-in-class TRPC3/6/7 inhibitor entering Phase IIa in myocardial reperfusion injury

Adiatiyp — I ii st-iii - class TRP c5/0/7 iii iiibitoi enteriiig Phase na iii iiiyocardiai repei

- Significant unmet need in myocardial infarction reperfusion injury
  No approved therapy; major driver of long-term heart failure
- Millions receive PCI with no protection from injury
- Xolatryp<sup>™</sup> selective TRPC3/6/7 inhibitor
- Targets validated TRPC biology (Boehringer Ingelheim Phase II success)
- Adjunct to PCI; composition-of-matter patent pending
- Strong preclinical efficacy in ischemia-reperfusion animal model
- Safe and well-tolerated in Phase I healthy human study
- Phase IIa imminent; HREC submitted, IND submission pending
- Partnerships: US DoD, UNSW; well-capitalised
- First to bring TRPC biology into cardiology
- Large market + validated target + high-impact catalysts
- Platform optionality across TRPC-driven diseases
- High calibre governing and scientific advisory boards







Advantage